Skip to Main Content

Author Details

Koen Degeling
Cancer Health Services Research, The University of Melbourne
2017
27
8
PMIDPaper TitleJournal TitlePublished Year
37608228Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia.Appl Health Econ Health Policy2024
36464923Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.Asia Pac J Clin Oncol2023
37964874Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach.Front Pharmacol2023
37958401Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer-A Clinical Vignette Study.Cancers (Basel)2023
36721219Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review.Cost Eff Resour Alloc2023
35031089Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer.Value Health2022
35406555Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance.Cancers (Basel)2022
36063280Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.Target Oncol2022
35158410Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.Eur J Haematol2022
34973103Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation.Eur Radiol2022
33440749Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late.Diagnostics (Basel)2021
33518027Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening.Value Health2021
33567163An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.Asia Pac J Clin Oncol2021
34838271Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.Value Health2021
34089503Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.Pharmacoeconomics2021
34337517Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review.Eur Urol Open Sci2021
33214711Evaluating the resource implications of different service delivery models for offering additional genomic findings.Genet Med2021
32319026Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review.Pharmacoeconomics2020
32690011Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.Health Qual Life Outcomes2020
32803720Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.Pharmacoeconomics2020
32428428Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process.Med Decis Making2020
30426801A scoping review of metamodeling applications and opportunities for advanced health economic analyses.Expert Rev Pharmacoecon Outcomes Res2019
30799693Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer.Med Decis Making2019
30317148Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients.Cancer Epidemiol2018
27978765A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models.Expert Rev Pharmacoecon Outcomes Res2017
29241901Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.Value Health2017
29246192Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models.BMC Med Res Methodol2017
  • 1 - 27 of 27

Recommended Authors

Holly E Hartman
Case Western Reserve University
Career Start Year 2018
Number of shared co-authors 1
Nathaniel Hendrix
Harvard T.H. Chan School of Public Health
Career Start Year 2017
Number of shared co-authors 0
Jessica A Lavery
Memorial Sloan Kettering Cancer Center
Career Start Year 2015
Number of shared co-authors 1
Seamus Kent
National Institute for Health and Care Excellence
Career Start Year 2013
Number of shared co-authors 0
Donna R Rivera
Oncology Center of Excellence
Career Start Year 2012
Number of shared co-authors 0
Michael J Crowther
8University of Leicester
Career Start Year 2012
Number of shared co-authors 0
Bart S Ferket
Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai
Career Start Year 2010
Number of shared co-authors 0
Jeff Round
Institute of Health Economics, University of Alberta
Career Start Year 2010
Number of shared co-authors 0
Mike Paulden
School of Public Health, University of Alberta
Career Start Year 2009
Number of shared co-authors 0
Kelley M Kidwell
University of Michigan School of Public Health ann arbor
Career Start Year 2009
Number of shared co-authors 0
Brian P Hobbs
Dell Medical School, University of Texas at Austin
Career Start Year 2008
Number of shared co-authors 0
Suja S Rajan
UTHealth School of Public Health
Career Start Year 2008
Number of shared co-authors 0
James Buchanan
Health Economics Research Centre, University of Oxford
Career Start Year 2007
Number of shared co-authors 1
Sunita Ghosh
Cross Cancer Institute
Career Start Year 2006
Number of shared co-authors 1
Rebecca A Hubbard
Perelman School of Medicine, The University of Pennsylvania
Career Start Year 2005
Number of shared co-authors 0
Nicholas Mitsakakis
Institute of Health Policy Management and Evaluation, University of Toronto
Career Start Year 2003
Number of shared co-authors 0
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 2
Pari V Pandharipande
The Ohio State University College of Medicine
Career Start Year 2001
Number of shared co-authors 0
Sarah Wordsworth
Health Economics Research Centre, University of Oxford
Career Start Year 1997
Number of shared co-authors 1
Deborah Schrag
Memorial-Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Craig C Earle
Odette Cancer Centre
Career Start Year 1996
Number of shared co-authors 0
Christopher McCabe
Queens University Belfast
Career Start Year 1996
Number of shared co-authors 0
Ben van Hout
University of Sheffield
Career Start Year 1993
Number of shared co-authors 0
Ewout W Steyerberg
Leiden University Medical Center
Career Start Year 1992
Number of shared co-authors 1
David L Veenstra
University of Washington
Career Start Year 1992
Number of shared co-authors 0
Madhu Mazumdar
Icahn School of Medicine at Mount Sinai
Career Start Year 1992
Number of shared co-authors 0
Anna N A Tosteson
Dartmouth Cancer Center
Career Start Year 1988
Number of shared co-authors 0
Mark S Roberts
School of Public Health, University of Pittsburgh
Career Start Year 1988
Number of shared co-authors 0
Benjamin Djulbegovic
Medical University of South Carolina
Career Start Year 1985
Number of shared co-authors 0
Donald A Berry
MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 0

Collaborators

Maarten J IJzerman
Technical Medical Centre, University of Twente
Co-authored papers 23
Martijn G H van Oijen
University of Amsterdam, Cancer Center Amsterdam
Co-authored papers 2
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Co-authored papers 2
Amanda Pereira-Salgado
the University of Melbourne
Co-authored papers 2
Clara Gaff
Murdoch Children's Research Institute
Co-authored papers 2
Peter Kuhn
University of Tubingen
Co-authored papers 1
Arun A Azad
Peter MacCallum Cancer Centre
Co-authored papers 1
Niven Mehra
Radboud university medical center
Co-authored papers 1
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Gavin M Wright
St. Vincent's Hospital, University of Melbourne
Co-authored papers 1
Release 1.2